Transcriptomic drug-response gene signatures are informative for the stratification of patients for clinical trials.

导出原文传递

翻译打印收藏纠错

第一作者： Paul S,Foster

第一单位： School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia; Hunter Medical Research Institute, New Lambton Heights, Australia. Electronic address: Paul.Foster@newcastle.edu.au.

作者： Paul S,Foster ^[1] ; Jessica L,Barnes ^[2] ; Hock L,Tay ^[2] ; Peter G,Gibson ^[3]

作者单位： School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia; Hunter Medical Research Institute, New Lambton Heights, Australia. Electronic address: Paul.Foster@newcastle.edu.au. ^[1] School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia; Hunter Medical Research Institute, New Lambton Heights, Australia. ^[2] School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, Australia; Hunter Medical Research Institute, New Lambton Heights, Australia. ^[3]

关键词 Atopic dermatitis IL-22 T(H)22 asthma subtypes fezakinumab transcriptomics

主题词皮炎, 特应性(Dermatitis, Atopic);人类(Humans);药用制剂(Pharmaceutical Preparations)

DOI 10.1016/j.jaci.2021.09.021

PMID 34582880

发布时间 2022-02-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交